NAD+, NADH, NADP+: The Coenzyme Forms Explained

NAD+ vs NADH vs NADP — three abbreviations that appear on almost every supplement label targeting cellular energy or longevity, yet most consumers cannot distinguish them. These molecules are not interchangeable. They represent different redox states and metabolic roles within your cells, and misunderstanding their functions leads to confusion about what NMN supplementation actually does. This article breaks down the biochemistry, the evidence from human trials, and what it means for anyone considering a nicotinamide mononucleotide supplement.

The Evidence Base

Human data on NAD+ precursors has expanded rapidly since 2020. The key question is not whether NMN raises NAD+ levels — it does — but whether that elevation translates into clinically meaningful outcomes.

Yoshino et al. (2021) conducted a randomized, double-blind, placebo-controlled trial in 25 postmenopausal women with prediabetes. Ten weeks of NMN supplementation at 250 mg daily increased muscle insulin sensitivity, improved insulin signaling, and upregulated muscle NAD+ biosynthesis. This remains one of the strongest human studies because it used a controlled design and measured tissue-level effects via muscle biopsies.

Igarashi et al. (2022) extended this to healthy older men, using 250 mg NMN twice daily for 12 weeks. The trial found elevated blood NAD+ levels and improved muscle function metrics including gait speed and grip strength. Notably, this was a randomized, placebo-controlled study in a Japanese population, adding geographic diversity to the evidence base.

Irie et al. (2020) provided safety and pharmacokinetic data in healthy Japanese men, showing that oral NMN at up to 500 mg daily was well tolerated and increased blood NAD+ metabolites. Liao et al. (2021) focused on exercise performance, finding that 300–1200 mg NMN daily for six weeks enhanced aerobic capacity in amateur runners. Niu et al. (2023) added metabolic and telomere data in a middle-aged cohort, though the study was shorter and the telomere findings were exploratory.

Gomes et al. (2013) established the foundational mechanistic link: declining NAD+ disrupts nuclear-mitochondrial communication via sirtuin-dependent pathways, creating a pseudohypoxic state that accelerates aging phenotypes. This was animal and cellular work, not human clinical data, but it frames why NAD+ restoration matters.

The Mechanism

NAD stands for nicotinamide adenine dinucleotide. The "+" in NAD+ indicates its oxidized state — it carries a positive charge and functions as an electron acceptor. When NAD+ accepts electrons and a hydrogen ion, it becomes NADH, the reduced form. This redox cycling is not decorative chemistry; it is the core mechanism by which cells transfer energy from nutrients to ATP.

Here is where the distinction becomes critical. NAD+ and NADH are a redox pair. The ratio of NAD+ to NADH determines the metabolic tone of a cell. High NAD+ favors oxidative metabolism, sirtuin activation, and repair pathways. High NADH signals energy abundance but can also indicate reductive stress if the ratio skews too far. You do not want simply more NADH; you want the correct balance, which requires sufficient NAD+ as the substrate pool.

NADP+ and its reduced form NADPH are chemically similar but functionally distinct. A phosphate group added at the 2' position of the adenosine ribose makes NADP+ a separate coenzyme recognized by different enzymes. NADPH primarily serves reductive biosynthesis — fatty acid synthesis, cholesterol production, and antioxidant defense via glutathione regeneration. The NADP+/NADPH pool operates largely independently of the NAD+/NADH pool, though they share biosynthetic origins from tryptophan, nicotinic acid, nicotinamide, and nicotinamide riboside.

NMN enters this pathway as a direct precursor. It is converted to NAD+ in one enzymatic step by NMNAT (nicotinamide mononucleotide adenylyltransferase). This bypasses the rate-limiting enzyme NAMPT in the NAD salvage pathway, which is why NMN supplementation has gained attention over simpler precursors like niacin. For a broader view of how different precursors compare, see our NAD Precursor Comparison.

What Each Form Actually Does

NAD+: The Oxidized Signal

NAD+ is not merely a fuel carrier. It is a signaling molecule. Sirtuins, PARPs, and CD38 all consume NAD+ as a substrate. Sirtuin activation links NAD+ to mitochondrial biogenesis, DNA repair, and metabolic flexibility. PARP activation during DNA damage depletes NAD+, creating a trade-off between repair and energy metabolism. CD38, a membrane-bound NADase, increases with age and contributes to the NAD+ decline observed in multiple tissues.

The Gomes et al. (2013) study showed that NAD+ depletion in older mice mimicked hypoxia at the molecular level, even when oxygen was plentiful. Restoring NAD+ via NMN reversed this pseudohypoxic state and improved mitochondrial function. This is animal data, but it provides the mechanistic rationale for human trials.

NADH: The Reduced Carrier

NADH carries electrons to the electron transport chain. Without NADH, complex I of the mitochondria cannot generate the proton gradient that drives ATP synthesis. However, NADH cannot directly activate sirtuins or PARPs. Supplementing with NADH has been attempted, but oral NADH is poorly absorbed and unstable. The cell maintains separate pools, and simply adding NADH does not reliably raise the NAD+ pool available for signaling.

This distinction matters for supplement selection. Products claiming to deliver "NADH for energy" are working through a different mechanism than NMN, which raises the total NAD+ pool from which both NAD+ and NADH are drawn.

NADP+/NADPH: The Reductive Shield

NADPH is the primary intracellular reducing agent. It powers the regeneration of glutathione, thioredoxin, and catalase — the core antioxidant enzyme systems. The NADP+ form is the oxidized reservoir. Unlike NAD+, NADP+ is not a major sirtuin substrate. Its role is metabolic: keeping biosynthetic pathways supplied with reducing equivalents and maintaining redox homeostasis under oxidative stress.

There is no direct human evidence that NMN supplementation substantially alters the NADP+/NADPH ratio. The salvage pathway enzymes show some preference for NAD+ synthesis, and the NADP+ pool is maintained through separate regulatory mechanisms. This is an area where human data is limited.

Human Trial Data: What We Know

The table below summarizes the key human NMN trials relevant to NAD+ biology. All studies used oral NMN and measured blood or tissue outcomes.

Study	Design	Population	NMN Dose	Duration	Primary Outcome	Evidence Quality
Yoshino et al. (2021)	RCT, double-blind, placebo-controlled	25 prediabetic women	250 mg/day	10 weeks	Increased muscle insulin sensitivity	High
Igarashi et al. (2022)	RCT, double-blind, placebo-controlled	42 healthy older men	250 mg twice daily	12 weeks	Elevated blood NAD+, improved muscle function	High
Irie et al. (2020)	Single-arm and RCT phases	10 healthy men	Up to 500 mg/day	14–31 days	Safety, tolerability, metabolite elevation	Moderate
Liao et al. (2021)	RCT, double-blind	48 amateur runners	300–1200 mg/day	6 weeks	Enhanced aerobic capacity (VO2 metrics)	Moderate
Niu et al. (2023)	RCT	80 middle-aged adults	300 mg/day	8 weeks	Metabolic shifts, exploratory telomere data	Moderate

Two patterns emerge. First, doses between 250 mg and 500 mg daily consistently raise blood NAD+ metabolites. Second, functional outcomes — insulin sensitivity, muscle performance, aerobic capacity — appear at these same doses, suggesting a threshold effect rather than linear dose-escalation. Liao et al. (2021) tested up to 1200 mg and found benefits across the range, but the lower doses performed nearly as well, making the optimal human dose an open question.

For readers interested in mitochondrial support beyond NAD+ precursors, our guide to Mitochondria Health Supplements covers complementary strategies.

Who Benefits Most

The evidence is not uniform across populations. The strongest human data support NMN supplementation for:

Older adults with declining metabolic flexibility. Igarashi et al. (2022) demonstrated improved muscle function in healthy men aged 65 and older. The mechanism aligns with the Gomes et al. (2013) finding that NAD+ decline drives age-related mitochondrial dysfunction.

Individuals with prediabetic insulin resistance. Yoshino et al. (2021) showed that NMN improved muscle insulin sensitivity in women with elevated HbA1c. This was not a diabetes treatment trial, but the effect size was meaningful and measured directly in muscle tissue.

Recreational athletes seeking aerobic gains. Liao et al. (2021) found that NMN improved VO2 and ventilatory thresholds in runners. The effect was most pronounced at higher doses, but even 300 mg daily showed benefit. This suggests NMN may support oxygen utilization efficiency, consistent with its role in mitochondrial NAD+ pools.

Healthy adults in the "pre-aging" phase. Niu et al. (2023) targeted adults aged 40–60 and found metabolic shifts and preliminary telomere data. The study was shorter and the telomere findings require replication, but it extends the demographic relevance beyond elderly populations.

Who does not have strong evidence? Young, healthy individuals with normal NAD+ levels. No trial has shown dramatic benefits in this group, and the Irie et al. (2020) safety data suggest that NMN is metabolically neutral rather than enhancing in already-optimized systems.

Practical Takeaways

• NAD+ and NADH are a redox pair, not interchangeable supplements. NAD+ drives signaling; NADH carries electrons for ATP production. NADP+/NADPH operates in a separate biosynthetic and antioxidant pool.
• Oral NMN reliably raises blood NAD+ metabolites in humans at doses of 250–500 mg daily. This is supported by multiple RCTs across different populations.
• Functional benefits — insulin sensitivity, muscle function, aerobic capacity — have been demonstrated in specific groups, but not universally across all ages and health states.
• NADH supplements are poorly absorbed and do not substitute for NAD+ precursors like NMN. The redox state matters more than total quantity.
• For those considering supplementation, a product providing 1000 mg NMN daily supplies a dose above the studied range, though human trials have not specifically tested this exact amount. Bio:sudo NMN 1000mg provides a single-tablet option for individuals who prefer higher-dose convenience, though the 250–500 mg range has the strongest direct trial support.
• NMN is not a substitute for exercise, sleep, or caloric moderation. These lifestyle factors also raise NAD+ through independent pathways, including AMPK activation and NAMPT upregulation.

Bottom Line

NAD+, NADH, and NADP+ are distinct coenzyme forms with non-overlapping primary roles. Human trials show that NMN supplementation raises NAD+ levels and can improve metabolic and muscle function in older and prediabetic populations, but the evidence does not yet support universal benefit in young, healthy adults. The biochemistry is clear; the clinical translation remains a work in progress.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---